# Human Models of Selective Insulin Resistance: Alpelisib, Part I

> **NCT06354088** · PHASE1 · RECRUITING · sponsor: **Columbia University** · enrollment: 32 (estimated)

## Conditions studied

- Insulin Resistance
- Prediabetic State
- Overweight and Obesity
- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Alpelisib 300 mg
- **DRUG:** Placebo
- **DRUG:** [1-13C] sodium acetate
- **DRUG:** [6,6-2H2] D-glucose
- **DIETARY_SUPPLEMENT:** Nestlé BOOST Plus

## Key facts

- **NCT ID:** NCT06354088
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-24
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06354088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06354088, "Human Models of Selective Insulin Resistance: Alpelisib, Part I". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06354088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*